This week in drug discovery (17-21 March)
News round-up for 17-21 March by DDW Senior Digital Content Editor Diana Spencer.
This week the DDW news round-up takes a look at developments in cancer research, including AZ’s acquisition of EsoBiotec, positive trial results for an allogeneic T-cell therapy, and a new drug target for glioblastoma.
The top stories:
AstraZeneca acquires in vivo cell therapy developer
EsoBiotec, a biotechnology company developing in vivo cell therapies, is to be acquired by AstraZeneca.
Allogeneic T-cell therapy doubles rate of survival free from GvHD
Biotechnology company Orca Bio has revealed positive results from the Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with haematological malignancies.
Study identifies new therapeutic target for glioblastoma
Scientists have demonstrated that glioblastoma (GBM) tumour stem cells became less able to proliferate and invade tissues when the production of the prion protein was blocked, highlighting a potential new therapeutic target.
Promising drug candidates for previously ‘undruggable’ cancer target
Reportedly for the first time, researchers from the University of Bath have identified promising drug candidates that bind irreversibly with a notoriously ‘undruggable’ cancer protein target, permanently blocking it.
